



G1 control
G2 CR194L4 100mg/kg iv q3d*6
G3 CR194A6 100mg/kg iv q3d*3
G4 CR194N5 100mg/kg iv q3d*3
Average body weight (g)
28
26
24
22
20
18
16
14
12
d1
d4
d7
d11
d14
d18
d21
d25
d28
Days post grouping

A



G1 control
G2 CR194L4 100mg/kg iv q3d*6
G3 CR194A6 100mg/kg iv q3d*3
Average tumor volume (mm3)
2500
2000
1500
1000
500
0
d1
d4
d7
d11
d14
d18
d21
d25
d28
Days post grouping

B

Fig. 1



Change in the body weight of the mice over the administration time (mean ± standard error)
Body weight (g)
30
29
28
27
26
25
24
23
22
21
20
19
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Days after the start of treatment
Group-1 vehicle 0mg/kg qw*3 iv
Group-2 CR194AX 150mg/kg qw*3 iv
Group-3 CR194AX 100mg/kg qw*3 iv
Group-4 CR194AX 50mg/kg q3d*6 iv
Group-5 CR194AX 50mg/kg qw*3 iv
Group-6 CR194AX 25mg/kg q3d*6 iv

A



Change in the body weight of the mice from the initial body weight over the administration time (mean ± standard error)
Body weight change (%)
15
10
5
0
-5
-10
-15
-20
-25
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Days after the start of treatment
Group-1 vehicle 0mg/kg qw*3 iv
Group-2 CR194AX 150mg/kg qw*3 iv
Group-3 CR194AX 100mg/kg qw*3 iv
Group-4 CR194AX 50mg/kg q3d*6 iv
Group-5 CR194AX 50mg/kg qw*3 iv
Group-6 CR194AX 25mg/kg q3d*6 iv

B

Fig. 2


Body weight change (%)
30
25
20
15
10
5
0
-5
-10
-15
0
2
4
6
8
10
12
14
Days after the start of treatment
G1:Control
G2:CR194AX 50mg/kg single dose
G3:CR194AX 100mg/kg single dose
G4:CR194X3 150mg/kg single dose
G5:CR194X3 200mg/kg single dose

A


Food weight (g)
25
20
15
10
5
0
6
8
10
12
14
Days after the start of treatment
G1:Control
G2:CR194AX 50mg/kg single dose
G3:CR194AX 100mg/kg single dose
G4:CR194X3 150mg/kg single dose
G5:CR194X3 200mg/kg single dose

B

Fig. 3